Undisclosed ANKET therapeutic / Sanofi, Innate - LARVOL DELTA

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results (Businesswire) - "€15 million investment by Sanofi, in addition to the ongoing partnership including the development of BCMA targeting ANKET program in autoimmune indications....The Phase 1/2 clinical trial evaluating IPH6501 in B-cell Non-Hodgkin’s lymphoma (B-NHL) is ongoing. The study is planned to enroll up to 184 patients. Clinical sites are open in the US, Australia and France and the first safety and preliminary activity data are expected in late 2025....The Phase 1 will assess the safety, tolerability, and preliminary efficacy of IPH4502 in advanced solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers....A Trial in Progress Poster will be shared at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in June 2025."

Financing • P1/2 data • Trial status • Breast Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Urothelial Cancer